Raphael Mechoulam

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Retrieved on: 
Wednesday, July 28, 2021
Medicinal plants, Psychoactive drugs, Health sciences, Entheogens, Euphoriants, Herbalism, Cannabis smoking, Medicine, Cannabis, Raphael Mechoulam, Medical cannabis, Effects of cannabis

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.

Key Points: 
  • MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.
  • As part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), Sir Marc Feldmanns (the Companys Co-Executive Chairman and Co-Founder) laboratory, and 180 Life Sciences scientists, identified the non-psychoactive CBD analogue as a lead molecule in the Companys SCA platform.
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Prof Raphael Mechoulam, meets all the criteria desirable to advance to clinical development.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.

GCANRx Announces Collaboration with Renowned Cannabis Research Lab

Retrieved on: 
Tuesday, March 16, 2021
Medicinal plants, Entheogens, Euphoriants, Psychoactive drugs, Cannabis smoking, Herbalism, Cannabis, Health sciences, Effects of cannabis, Medical cannabis, Raphael Mechoulam, Cannabinoid

Phytor is led by Dr. Yehoshua Maor, a pharmacologist, toxicologist and cannabis expert who completed his graduate studies at the Hebrew University under the supervision of renowned professor, Dr. Raphael Mechoulam, one of the most acclaimed cannabis researchers, and known throughout the world as the Father of Cannabis Research''.

Key Points: 
  • Phytor is led by Dr. Yehoshua Maor, a pharmacologist, toxicologist and cannabis expert who completed his graduate studies at the Hebrew University under the supervision of renowned professor, Dr. Raphael Mechoulam, one of the most acclaimed cannabis researchers, and known throughout the world as the Father of Cannabis Research''.
  • As a graduate student he received awards for outstanding scientific presentations at the International Cannabis Research Society (ICRS).
  • Under his direction, Phytor has become a world renowned cannabis R&D facility with an established team of multidisciplinary PhDs skilled in advanced science and research of pharmacological, agricultural and genetic characteristics of cannabinoids.
  • We are delighted to be joining forces with GCANRx to collaborate on cutting edge cannabinoid and botanical-based therapies.

CBD Nation, Available August 25 On Amazon And Video On Demand, Examines The Highest Levels Of Scientific Research And Medical Evidence Surrounding The World's Most Politicized Plant: Cannabis

Retrieved on: 
Monday, August 10, 2020
Cannabinoids, Drugs, Resorcinols, Cannabis, Natural phenols, Analgesics, Anticonvulsants, Cannabidiol, Organ systems, Raphael Mechoulam, CBD

"We published our findings thirty-seven years ago: cannabidiol (CBD) blocks epileptic attacks in patients.

Key Points: 
  • "We published our findings thirty-seven years ago: cannabidiol (CBD) blocks epileptic attacks in patients.
  • Nothing for thirty years," states Raphael Mechoulam, President of The Multidisciplinary Center for Cannabinoid Research at The Hebrew University of Jerusalem.
  • "Nothing happened until desperate parents like those in this film did their own research and found out that cannabidiol can help children with epilepsy.
  • If the world chooses to not look at all of the science, it is not ignorance it's negligence."

Medicinal Genomics Announces Raphael Mechoulam, the Father of Cannabis Research, Will Headline CannMed 2019, September 23-24, in Pasadena, CA

Retrieved on: 
Tuesday, August 20, 2019
Cannabis, Medicinal plants, Health, Entheogens, Articles, Herbalism, Cannabis smoking, Euphoriants, Raphael Mechoulam, Medical cannabis, Effects of cannabis, Legality of cannabis

Raphael Mechoulam was born in Bulgaria in 1930 and immigrated with his family to Israel in 1949 where he later studied chemistry.

Key Points: 
  • Raphael Mechoulam was born in Bulgaria in 1930 and immigrated with his family to Israel in 1949 where he later studied chemistry.
  • And he is one of the reasons so many of the greatest minds in cannabis choose to share their work at CannMed.
  • Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products.
  • To support this work, Medicinal Genomics also produces CannMed, a gathering of cannabis leaders, dedicated to furthering thestate of the art in medicinal cannabis, and Kannapedia, the world's most complete public cannabis strain database.For more information, please visit www.medicinalgenomics.com .

Medicinal Genomics Announces Raphael Mechoulam, the Father of Cannabis Research, Will Headline CannMed 2019, September 23-24, in Pasadena, CA

Retrieved on: 
Tuesday, August 20, 2019
Cannabis, Medicinal plants, Health, Entheogens, Articles, Herbalism, Cannabis smoking, Euphoriants, Raphael Mechoulam, Medical cannabis, Effects of cannabis, Legality of cannabis

Raphael Mechoulam was born in Bulgaria in 1930 and immigrated with his family to Israel in 1949 where he later studied chemistry.

Key Points: 
  • Raphael Mechoulam was born in Bulgaria in 1930 and immigrated with his family to Israel in 1949 where he later studied chemistry.
  • And he is one of the reasons so many of the greatest minds in cannabis choose to share their work at CannMed.
  • Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products.
  • To support this work, Medicinal Genomics also produces CannMed, a gathering of cannabis leaders, dedicated to furthering thestate of the art in medicinal cannabis, and Kannapedia, the world's most complete public cannabis strain database.For more information, please visit www.medicinalgenomics.com .

Yissum Hosts First-of-its-Kind Conference to Drive Academic-industry Collaboration in Cannabis Research & Development

Retrieved on: 
Wednesday, May 1, 2019
Medicinal plants, Cannabis, Medicine, Cannabis smoking, Health, Entheogens, Euphoriants, Herbalism, Hebrew University of Jerusalem, Raphael Mechoulam, Cannabis industry, Etymology of cannabis

JERUSALEM, May 1, 2019 /PRNewswire/ -- Yissum, the technology transfer company of The Hebrew University of Jerusalem, is hosting a first-of-its kind conference to drive academic-industry collaboration across multiple cannabis-related research and development areas.

Key Points: 
  • JERUSALEM, May 1, 2019 /PRNewswire/ -- Yissum, the technology transfer company of The Hebrew University of Jerusalem, is hosting a first-of-its kind conference to drive academic-industry collaboration across multiple cannabis-related research and development areas.
  • The one-day conference will bring Hebrew University researchers and industry professionals together to focus on furthering cannabis research for future commercialization.
  • During the event on May 1, Yissum will also honor Hebrew University Professor Raphael Mechoulam for his achievements in advancing collaboration between academia and the medical cannabis industry.
  • Hebrew University is a major partner in the development of the city's cannabis market, furthering the development of new technologies and strengthening the biotech and cannabis ecosystem in Jerusalem."

OurCrowd Announces Winners of Second Annual Maimonides Award for Lifetime Achievement at 2019 Global Investor Summit

Retrieved on: 
Thursday, March 7, 2019
Technology, Other Technology, Health, Alternative medicine, Research, Other Science, Science, OurCrowd, Science and technology in Israel, Drugs, Economy, Israeli Jews, Raphael Mechoulam, Tetrahydrocannabinol, Startup company, Cannabinoid, Avraham

OurCrowd , a leading global investment platform and Israels most active venture investor, announced today Professor Raphael Mechoulam and Professor Avraham Baniel as the winners of the second annual OurCrowd Maimonides Award for Lifetime Achievement in Science, Leadership and Menschlichkeit*.

Key Points: 
  • OurCrowd , a leading global investment platform and Israels most active venture investor, announced today Professor Raphael Mechoulam and Professor Avraham Baniel as the winners of the second annual OurCrowd Maimonides Award for Lifetime Achievement in Science, Leadership and Menschlichkeit*.
  • His contributions of over 50 years of research include the isolation and synthesis of THC and the identification of the endocannabinoid system.
  • This announcement was made at the 2019 OurCrowd Global Investor Summit in Jerusalem, the largest technology showcase in Israel with over 170 startups and 17,000 registered attendees.
  • About the 2019 OurCrowd Global Investor Summit:The OurCrowd Global Investor Summit, Where the startup world gathers.